← Browse by Condition
Medical Condition

advanced solid tumors

Total Trials
35
Recruiting Now
35
Trial Phases
EARLY_Phase 1, Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for advanced solid tumors sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — advanced solid tumors Clinical Trials

How many clinical trials are currently recruiting for advanced solid tumors?
ClinicalMetric currently tracks 35 actively recruiting clinical trials for advanced solid tumors, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 35. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for advanced solid tumors?
advanced solid tumors research spans Phase 1 (31 trials), Phase 2 (16 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a advanced solid tumors clinical trial?
Eligibility criteria for advanced solid tumors trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
31
Phase 2
16
Top Sponsors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 3 trials
Shanghai Hengrui Pharmaceutical Co., Ltd. 3 trials
ModernaTX, Inc. 2 trials
Changchun GeneScience Pharmaceutical Co., Ltd. 2 trials
Beijing Geekgene Technology Co., LTD 1 trial

Recruiting Clinical Trials

NCT07414316 EARLY_Phase 1
Recruiting
A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.
Enrollment
10 pts
Location
China
Sponsor
Beijing Geekgene Technology Co...
View Trial →
NCT02693535 Phase 2
Recruiting
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Enrollment
4,200 pts
Location
United States, Puert...
Sponsor
American Society of Clinical O...
View Trial →
NCT07793214
Recruiting
ET-SPACE Whole-Body Infrared Hyperthermia in Patients With Advanced Solid Tumors
Enrollment
500 pts
Location
China
Sponsor
Zhejiang Hospital
View Trial →
NCT07004296 Phase 1
Recruiting
A Study of HDM2005 in Patients With Advanced Solid Tumor
Enrollment
72 pts
Location
China
Sponsor
Hangzhou Zhongmei Huadong Phar...
View Trial →
NCT07556653 EARLY_Phase 1
Recruiting
Allogeneic WTX-212C in Advanced Solid Tumors
Enrollment
24 pts
Location
China
Sponsor
Zhejiang Provincial People's H...
View Trial →
NCT06736327 Phase 1
Recruiting
A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors
Enrollment
180 pts
Location
China
Sponsor
Sichuan Kelun-Biotech Biopharm...
View Trial →
NCT06686745 Phase 1
Recruiting
Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors
Enrollment
130 pts
Location
China
Sponsor
Jiangsu Simcere Pharmaceutical...
View Trial →
NCT07545265 Phase 1, Phase 2
Recruiting
SKB565 for Injection in Advanced Solid Tumors
Enrollment
180 pts
Location
China
Sponsor
Sichuan Kelun-Biotech Biopharm...
View Trial →
NCT05379985 Phase 1, Phase 2
Recruiting
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Enrollment
754 pts
Location
United States
Sponsor
Revolution Medicines, Inc.
View Trial →
NCT06474455 Phase 1, Phase 2
Recruiting
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors
Enrollment
156 pts
Location
China
Sponsor
Shanghai Hengrui Pharmaceutica...
View Trial →
NCT07046650 Phase 2
Recruiting
Multi-cohort, Single-arm, Phase II Study of the Efficacy and Side Effects of Cisplatin Plus Gemcitabine in the Treatment of PD1 Failure or Intensive Treatment of Some Rare Tumors
Enrollment
84 pts
Location
China
Sponsor
Sheng Zhang
View Trial →
NCT04222413 Phase 1
Recruiting
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Enrollment
116 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT05533697 Phase 1, Phase 2
Recruiting
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Enrollment
361 pts
Location
United States, Austr...
Sponsor
ModernaTX, Inc.
View Trial →
NCT06480552 Phase 1
Recruiting
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Enrollment
240 pts
Location
United States, Canad...
Sponsor
Teva Branded Pharmaceutical Pr...
View Trial →
NCT06832982 Phase 1
Recruiting
Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002
Enrollment
66 pts
Location
China
Sponsor
Shanghai Pushi Medical Science...
View Trial →
NCT06697197 Phase 1, Phase 2
Recruiting
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Enrollment
413 pts
Location
United States, Belgi...
Sponsor
Bristol-Myers Squibb
View Trial →
NCT07702162 Phase 1
Recruiting
A Clinical Study of PA5 in Patients With Advanced Solid Tumors
Enrollment
49 pts
Location
China
Sponsor
Chongqing Peg-Bio Biopharm Co....
View Trial →
NCT07161414 Phase 1
Recruiting
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
Enrollment
40 pts
Location
United States, South...
Sponsor
AstraZeneca
View Trial →
NCT05867420 Phase 1, Phase 2
Recruiting
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Enrollment
594 pts
Location
United States, China
Sponsor
AskGene Pharma, Inc.
View Trial →
NCT06819735 Phase 1, Phase 2
Recruiting
Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors
Enrollment
125 pts
Location
United States, Austr...
Sponsor
Domain Therapeutics Australia ...
View Trial →
NCT07266428 Phase 1, Phase 2
Recruiting
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
Enrollment
170 pts
Location
United States, Austr...
Sponsor
Ottimo Pharma Limited
View Trial →
NCT06880549 Phase 1
Recruiting
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
Enrollment
42 pts
Location
United States
Sponsor
ModernaTX, Inc.
View Trial →
NCT04967833 EARLY_Phase 1
Recruiting
A Study of GC101 TIL in Advanced Solid Tumors (TR)
Enrollment
20 pts
Location
China
Sponsor
Shanghai Juncell Therapeutics
View Trial →
NCT07744763 Phase 1, Phase 2
Recruiting
A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors
Enrollment
260 pts
Location
China
Sponsor
CSPC Megalith Biopharmaceutica...
View Trial →
NCT06840886 Phase 1
Recruiting
A Study of PHST001 in Advanced Solid Tumors
Enrollment
272 pts
Location
United States
Sponsor
Pheast Therapeutics
View Trial →
NCT06770569 Phase 1
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
Enrollment
100 pts
Location
Australia, China
Sponsor
Shandong Suncadia Medicine Co....
View Trial →
NCT07413328 Phase 1
Recruiting
HWS116 Monotherapy in Patients With Advanced Solid Tumors
Enrollment
56 pts
Location
China
Sponsor
Wuhan Humanwell Innovative Dru...
View Trial →
NCT06895928 Phase 2
Recruiting
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Enrollment
400 pts
Location
China
Sponsor
Shanghai Hengrui Pharmaceutica...
View Trial →
NCT07251166 Phase 1
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors
Enrollment
170 pts
Location
China
Sponsor
Changchun GeneScience Pharmace...
View Trial →
NCT06605222 Phase 1, Phase 2
Recruiting
A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
Enrollment
201 pts
Location
China
Sponsor
Shanghai Hengrui Pharmaceutica...
View Trial →
NCT06795412 Phase 1, Phase 2
Recruiting
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Enrollment
220 pts
Location
United States, Franc...
Sponsor
Pyxis Oncology, Inc
View Trial →
NCT07131202 Phase 1, Phase 2
Recruiting
A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors
Enrollment
130 pts
Location
China
Sponsor
Suzhou Forlong Biotechnology C...
View Trial →
NCT07252414 Phase 1
Recruiting
GenSci143 in Participants With Advanced Solid Tumors
Enrollment
180 pts
Location
China
Sponsor
Changchun GeneScience Pharmace...
View Trial →
NCT07156253 Phase 1
Recruiting
Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors
Enrollment
110 pts
Location
China
Sponsor
Hangzhou SynRx Therapeutics Bi...
View Trial →
NCT07459998 Phase 1, Phase 2
Recruiting
SKB103 for Injection in Advanced Solid Tumors
Enrollment
277 pts
Location
China
Sponsor
Sichuan Kelun-Biotech Biopharm...
View Trial →

Related Conditions

ovarian cancer (2) lymphoma non hodgkin (1) multiple myeloma (1) advanced solid tumors cancer (1) non small cell lung cancer nsclc (1) colorectal cancer crc (1) pancreatic ductal adenocarcinoma pdac (1) metastatic pancreatic cancer (1) pediatric solid tumor (1) advanced breast cancer (1) malignant peripheral nerve sheath tumor (1) colorectal neoplasms (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology